Users receive adequate directions for use
Risks are clearly communicated
Devices can be identified and traced
Labeling remains accurate, legible, and durable throughout use
A common misconception is that labeling refers only to the physical label affixed to the device or packaging. Under FDA law, the term “labeling” is broader.
A “label” refers to written, printed, or graphic matter on the immediate container of a device. “Labeling,” however, includes all written, printed, or graphic materials that accompany the device at any time while it is held for sale. This can include:
Packaging
Instructions for Use (IFU)
Inserts
User manuals
Brochures shipped with the device
Certain promotional materials
This distinction matters during inspections. FDA evaluates whether all labeling materials (not just the device label) are accurate, consistent, and aligned with the device’s cleared or approved intended use.
21 CFR Part 801 establishes baseline requirements for medical device labeling. These provisions address:
Adequate directions for use
Intended use definitions
Prominence and placement requirements
Prescription device exemptions
Required manufacturer identification
Part 801 defines what information must be present and how it must be presented to avoid misbranding. It also distinguishes between devices intended for lay users and those intended for healthcare professionals.
For prescription devices, 21 CFR 801.109 provides exemptions from certain directions-for-use requirements, provided specific conditions are met, including appropriate “Rx Only” designation and professional-use labeling.
For a more detailed overview, see our resource on Understanding 21 CFR Part 801 Labeling Requirements.
The FDA’s UDI Rule requires most medical devices to bear a Unique Device Identifier on the label and packaging. The UDI is composed of:
A Device Identifier (DI), which identifies the labeler and specific device version
A Production Identifier (PI), which may include lot number, serial number, manufacturing date, or expiration date
The UDI must appear in both human-readable and automatic identification and data capture (AIDC) format, such as a barcode. Certain reusable devices also require direct marking on the device itself.
In addition, manufacturers must submit device information to the Global Unique Device Identification Database (GUDID).
UDI requirements play a central role in traceability and recall management, making them one of the most operationally significant labeling obligations.
For a more detailed overview, see our supporting resource on UDI Compliance for Medical Device Labels.
While Part 801 governs labeling content, 21 CFR Part 820 governs how labeling is controlled within a manufacturer’s quality system.
Section 820.120 requires manufacturers to establish and maintain procedures to control labeling activities, including:
Label review and approval
Label inspection and verification
Label storage and segregation
Prevention of labeling mix-ups
Control number assignment and traceability
These controls are frequently reviewed during FDA inspections and are common sources of observations when documentation or reconciliation processes are inadequate.
For a more detailed overview, see our supporting resource on 21 CFR 820.120 Device Labeling Requirements for Medical Devices.
Although specific requirements vary based on device type and classification, FDA-compliant medical device labels typically include:
Device name
Intended use or indications
Manufacturer name and place of business
Lot number or serial number (when required for traceability)
Manufacturing date and/or expiration date (where applicable)
Unique Device Identifier (UDI)
Required warnings, precautions, and contraindications
Storage conditions, if necessary for safety or performance
Information must be presented in a manner that is not false or misleading and must be prominently displayed. Symbols may be used in certain cases, but when symbols are used without accompanying text, a glossary may be required.
It is also important to distinguish between what must appear on the device label versus what may be included in accompanying Instructions for Use. The label itself must contain essential identifying and safety information, while detailed operational instructions may appear in the IFU.
For a more detailed overview, see our supporting resource on Required Elements of an FDA-Compliant Medical Device Label or our Medical Device Labeling Symbols Glossary.
Medical devices are classified into Class I, Class II, or Class III based on risk.
Class I devices are subject to general controls, including basic labeling requirements. Many Class I devices are exempt from premarket submission but must still comply with labeling regulations and UDI requirements (unless specifically exempted).
Class II devices are subject to special controls and often require 510(k) clearance. Labeling for Class II devices must align precisely with cleared indications for use. Deviations between cleared intended use statements and commercial labeling can raise significant compliance concerns.
Class III devices, which typically require Premarket Approval (PMA), are subject to the highest level of scrutiny. Labeling content is reviewed as part of the approval process, and changes to labeling may require FDA notification or approval depending on their significance.
As device risk increases, regulatory scrutiny of labeling content and claims increases proportionally.
Labeling requirements extend beyond content accuracy. Labels must remain legible and attached under expected conditions of distribution, storage, and use.
For many devices, this means labels must withstand:
Sterilization processes
Exposure to chemicals or cleaning agents
Abrasion and handling
Temperature fluctuations
Moisture or humidity exposure
Inadequate label adhesion or barcode degradation can compromise traceability and create safety risks. Manufacturers are expected to validate that labels remain legible and scannable throughout the product’s intended lifecycle.
Durability considerations should be integrated early into material selection, adhesive choice, and print methodology to prevent post-market compliance issues.
FDA inspection findings frequently cite labeling-related deficiencies. Common issues include:
Inconsistent intended use language between labeling and cleared indications, which can suggest off-label promotion.
Incorrect or missing UDI information, including formatting errors or barcode readability failures.
Inadequate reconciliation of printed labels, leading to risk of mix-ups or unauthorized use.
Failure to segregate obsolete labels, resulting in outdated labeling entering distribution.
Insufficient documentation of label approval and revision history.
Many labeling compliance issues arise not from misunderstanding regulations but from weaknesses in operational controls and change management processes.
During inspections, FDA investigators often review:
Label approval records
Change history documentation
Reconciliation logs
UDI compliance
Device History Records (DHR)
Procedures governing label control
Manufacturers should be prepared to demonstrate that labeling is controlled, traceable, and consistent with regulatory submissions.
Inspection readiness depends heavily on clear documentation and disciplined execution of labeling procedures.
Even experienced manufacturers have questions about FDA medical device labeling requirements. For answers to common questions, explore our comprehensive Medical Device Labeling FAQ Page for detailed guidance on staying compliant with FDA labeling regulations.
Custom Labels for Medical Devices
UDI Compliant Solutions
Reach out and get in touch.
(800) 637-4487
sales@gmplabeling.com
5955 Granite Lake Drive Suite 150 Granite Bay, California 95746